HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 59, Number 11, December 10, 2002 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plested, C.P. Articles by Vincent, A. Search for Related Content PubMed PubMed Citation Articles by Plested, C.P. Articles by Vincent, A. Related Collections All Immunology Autoimmune diseases All Neuromuscular Disease Myasthenia

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG

From the Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Address correspondence and reprint requests to Prof. A. Vincent, Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK; e-mail: Angela.vincent{at}imm.ox.ac.uk

Background: Approximately 10% to 20% of patients with autoimmune MG do not have antibodies to the acetylcholine receptor (AChR), so-called seronegative MG (SNMG). IgG antibodies from up to 70% of SNMG patients bind to the muscle-specific receptor tyrosine kinase, MuSK. The plasmas and non-IgG fractions from SNMG patients (and some with AChR antibodies) also contain a factor, perhaps an IgM antibody, that inhibits AChR function, but it is not clear how this factor acts and whether it is related to the MuSK IgG antibodies.

Methods: The authors studied 12 unselected SNMG plasmas and their non-IgG fractions; seven were positive for MuSK IgG antibodies. Ion flux assays, electrophysiology, phosphorylation, and kinase assays were used to look at mechanisms of action.

Results: Eight of the 12 plasmas and their non-IgG fractions inhibited AChR function, but the inhibitory activity was transient and did not correlate with the presence of MuSK IgG antibodies. Two of three plasmas added outside of a cell-attached patch pipette inhibited AChR function within the patch, and these two plasmas also increased AChR phosphorylation.

Conclusions: The authors propose that a plasma factor(s) in SNMG patients, distinct from MuSK IgG antibodies, binds to a muscle membrane receptor and activates a second messenger pathway leading to AChR phosphorylation and reduced AChR function. Identifying the target for this factor should lead to improved diagnosis of MG in MuSK antibody-negative patients and may provide new insights into the function of the neuromuscular junction and pathophysiological mechanisms in MG.

This article has been cited by other articles:

				M. I. Leite, S. Jacob, S. Viegas, J. Cossins, L. Clover, B. P. Morgan, D. Beeson, N. Willcox, and A. Vincent IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis Brain, July 1, 2008; 131(7): 1940 - 1952. [Abstract] [Full Text] [PDF]

				M. I. Leite, M. Jones, P. Strobel, A. Marx, R. Gold, E. Niks, J. J.G.M. Verschuuren, S. Berrih-Aknin, F. Scaravilli, A. Canelhas, et al. Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody Status Am. J. Pathol., September 1, 2007; 171(3): 893 - 905. [Abstract] [Full Text] [PDF]

				A. C. Vincent, J. McConville, J. Newsom-Davis, J. M. Lindstrom, and A. G. Engel Is "seronegative" MG explained by autoantibodies to MuSK? Neurology, January 25, 2005; 64(2): 399 - 399. [Full Text] [PDF]

				H.-S. Wang Myasthenia Gravis: Generalized vs Ocular, and Children vs Adults Arch Neurol, October 1, 2003; 60(10): 1491 - 1491. [Full Text] [PDF]

				A. Evoli, P. A. Tonali, L. Padua, M. L. Monaco, F. Scuderi, A. P. Batocchi, M. Marino, and E. Bartoccioni Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis Brain, October 1, 2003; 126(10): 2304 - 2311. [Abstract] [Full Text] [PDF]

				A. Abicht and H. Lochmuller What's in the serum of seronegative MG and LEMS?: MuSK et al. Neurology, December 10, 2002; 59(11): 1672 - 1673. [Full Text] [PDF]